Results 61 to 70 of about 3,710 (152)

Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that
Scott A. Barman, Zsuzsanna Bordan, David J. R. Fulton   +2 more
wiley   +1 more source

Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent.
Anna Smukowska‐Gorynia, Sylwia Iwańczyk, Michał Ciurzyński, Marcin Waligóra, Marcin Kurzyna, Piotr Pruszczyk, Grzegorz Kopeć, Katarzyna Mizia‐Stec, Ilona Skoczylas, Łukasz Chrzanowski, Piotr Błaszczak, Katarzyna Ptaszyńska, Grzegorz Grześk, Ewa Malinowska, Małgorzata Peregud‐Pogorzelska, Michał Tomaszewski, Ewa Mroczek, Miłosz Jaguszewski, Ewa Lewicka, Katarzyna Widejko, Agnieszka Pawlak, Wojciech Jacheć, Zbigniew Gąsior, Katarzyna Betkier‐Lipińska, Judyta Winowska‐Józwa, Marta Banaszkiewicz, Tatiana Mularek‐Kubzdela   +26 more
wiley   +1 more source

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results

Рациональная фармакотерапия в кардиологии, 2020
The article is devoted to topical issues of management of patients with pulmonary arterial hypertension and strategies for switching to riociguat therapy in patients with insufficient clinical response against the background of phosphodiesterase type 5 ...
E. V. Filippov
doaj   +1 more source

Riociguat reduces and alters hyperoxia-induced lung inflammation.

, 2018
(A) Immunostaining for Mac-3, a macrophage marker. (B) The alveolar airspace macrophage population was increased by hyperoxia exposure as compared to normoxia. Administration of riociguat decreased macrophage count during hyperoxia.
Ronald Zambrano (5497406), Younghye Moon (200726), Shu Wu (492135), Shihua Luo (5497415), Yong Bao (296790), Luqing Wang (5257895), Merline Benny (5497403), Justin Percival (5497412), Ling Qin (68169), Fredrick Dapaah-Siakwan (5497409), Matthew R. Duncan (5497421), Keyur Donda (5497400), Karen Young (833929), Ruben Vaidya (5497418)   +13 more
core   +1 more source

Transitions From Parenteral Prostacyclin Analogues to Selexipag in Patients With Pulmonary Arterial Hypertension

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA's are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness.
Dalton J. Kuebel, Adele R. Collins, Arun Jose, Maria R. Guido, Jean M. Elwing   +4 more
wiley   +1 more source

Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats

Toxicology Reports
This study aimed to investigate the potential protective effects of riociguat, a soluble guanylyl cyclase (sGC) stimulator, on kidney function and structure in rats with acute kidney injury (AKI) induced by the chemotherapeutic drug doxorubicin (DX ...
Raya Al-Maskari, Aly M. Abdelrahman, Haytham Ali, Priyadarsini Manoj, Yousuf Al Suleimani   +4 more
doaj   +1 more source

Scientific Reports / The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats [PDF]

, 2018
In cirrhotic patients, portal hypertension (PHT) deteriorates survival, yet treatment options are limited. A major contributor to increased intrahepatic vasoconstriction in PHT is dysfunctional nitric-oxide signaling.
Supper, Paul, Stift, Judith, Philipp Königshofer, Thomas Reiberger, Schwabl, Philipp, David Bauer, Oberhuber, Georg, Paul Supper, Florian Riedl, Fuchs, Claudia Daniela, Aschauer, Stefan, Königshofer, Philipp, Judith Stift, Trauner, Michael, Georg Oberhuber, Markus Peck-Radosavljevic, Thorsten Gnad, Uschner, Frank Erhard, Diana Bonderman, Nataliya Rohr-Udilova, Hayden, Hubert, Stefan Aschauer, Trebicka, Jonel, Philipp Schwabl, Alexander Pfeifer, Pfeifer, Alexander, Michael Trauner, Jonel Trebicka, Brusilovskaya, Ksenia, Bonderman, Diana, Riedl, Florian, Reiberger, Thomas, Gnad, Thorsten, Rohr-Udilova, Nataliya, Podesser, Bruno Karl, Bauer, David, Frank Erhard Uschner, Bruno Karl Podesser, Peck-Radosavljevic, Markus, Hubert Hayden, Claudia Daniela Fuchs, Ksenia Brusilovskaya   +41 more
core   +1 more source

Observed Weight Gain in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Sotatercept, an activin signaling inhibitor for pulmonary arterial hypertension (PAH), has demonstrated significant improvements in clinical outcomes though its off‐target effects are still an area for discovery. Anecdotal increases in total body weight not attributable to fluid retention have been observed.
Rebecca A. Greene, Darlene Tat, Allyson Sherman‐Roe, Tiffaney Cayton, Jacqueline Lopes, Alexander Jorrin, James Klinger, Christopher J. Mullin, Kathryn Needle, William M. Oldham, Crossandra Osgood, Navneet Singh, Corey E. Ventetuolo   +12 more
wiley   +1 more source

Invasive Management for Acute‐on‐Chronic Thromboembolic Pulmonary Hypertension: Feasibility and Clinical Outcomes in a Single‐Center Cohort

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
In this single‐center cohort of 15 critically ill patients with acute‐on‐chronic thromboembolic pulmonary hypertension, invasive management with pulmonary endarterectomy and/or balloon pulmonary angioplasty was associated with substantial hemodynamic improvement.
Jun Yamashita, Ryosuke Ito, Sayo Ikeda, Koki Hasegawa, Yoshikazu Takeuchi, Tomohiro Kasahara, Naotaka Murata, Shun Suzuki, Hideaki Kanazawa, Yusuke Shimahara, Kazuhiro Satomi   +10 more
wiley   +1 more source

Riociguat for pulmonary hypertension

Pulmonary hypertension (PH) encompasses a group of diseases associated with progressively increasing pulmonary vascular resistance, right heart failure and premature death.
Seeger, W., Schermuly, R., Ghofrani, H. A., Voswinckel, R., Gall, H., Weissmann, N., Grimminger, F.   +6 more
core   +2 more sources